Table 3.
Comparisons of baseline characteristics between IDH-wt and IDH-mut long-term survivors.
| Variables | IDH-wt (n=17) | IDH-mut (n=27) | P value |
|---|---|---|---|
| Age at diagnosis (years) | 41.1 ± 12.3 | 41.3 ± 10.5 | 0.938 |
| Gender | 0.651 | ||
| Male | 10/17 | 14/27 | |
| KPS score | 80.0 ± 8.7 | 84.7 ± 7.4 | 0.115 |
| Tumor size (mm) | 52.4 ± 16.3 | 45.3 ± 19.2 | 0.213 |
| Tumor location | 0.351 | ||
| Frontal | 10/17 | 16/27 | |
| Temporal | 6/17 | 5/27 | |
| Parietal | 0/17 | 3/17 | |
| Occipital | 1/17 | 1/27 | |
| Others | 0/17 | 2/27 | |
| Laterality | 0.342 | ||
| Right | 8/17 | 17/27 | |
| Left | 8/17 | 7/27 | |
| Bilateral | 1/17 | 3/27 | |
| Enhancement | 0.036 | ||
| Solid | 14/17 | 12/27 | |
| Ring | 2/17 | 6/27 | |
| Irregular | 1/17 | 9/27 | |
| Cystic change | 0.022 | ||
| Yes | 6/17 | 19/27 | |
| Extent of resection | 0.380* | ||
| GTR | 16/17 | 22/27 | |
| Chemotherapy | 0.125* | ||
| Temozolomide | 16/17 | 20/27 | |
| Nimostine | 1/17 | 7/27 | |
| Radiotherapy | NA | ||
| Yes | 17/17 | 27/27 | |
| Recurrence pattern | 0.003* | ||
| Local | 3/8 | 19/20 | |
| MGMT promotor | 1.0 | ||
| Methylation | 12/17 | 12/17 | |
| 1q/19p co-polysomy | 0.018* | ||
| Yes | 1/17 | 8/18 | |
| Ki-67 index | 0.053 | ||
| High | 8/17 | 3/18 |
IDH, isocitrate dehydrogenase; KPS, Karnofsky performance scale; GTR, gross-total resection; MGMT, O6-methylguanine-DNA-methyltransferase; NA, not applicable.
*by Fisher exact test.